Positron emission tomography (PET)/computed tomography (CT) with 18 F-fluorodeoxyglucose (FDG) is widely used for post-therapeutic surveillance of malignant lymphoma. Debate still exists as to whether intravenous contrast media during the CT stage of a PET/CT scan should be used. The purpose of this study was to investigate the clinical value of contrast agent in PET/CT in patients with lymphoma following treatment.
Introduction
In the management of malignant lymphoma, diagnostic imaging is indispensable for creating an appropriate therapeutic strategy. Due to availability and low cost, computed tomography (CT) is the most commonly used imaging modality for evaluation of post-therapeutic condition, as well as initial staging before treatment. Iodine-based intravenous contrast material is often used during these scans to make interpretations more accurate and with confidence. However, it is difficult to evaluate the viability of lesions only by morphological information.
Positron emission tomography (PET) using 18 F-fluorodeoxyglucose (FDG) is a functional imaging tool, which detects viable lesions throughout the whole body. PET is thought to be useful for not only staging or restaging, but also for predicting prognosis of patients, especially after treatment [1, 2] . PET can reflect biological status of the lesions earlier than morphological changes occur, which is useful in making decisions for therapeutic strategies. Although morphological changes have been traditionally used as an indicator of post-therapeutic status, it is currently recommended that PET findings, together with morphological findings, should be considered after chemotherapy and/or radiation therapy [3, 4] . In order to overcome the lack of morphological information by PET, an inline PET-CT system has been developed, and metabolic information as well 5 as morphological status can be easily obtained at a single examination. This scanning method yields more findings that are accurate with higher confidence, as compared with CT alone or PET alone [5] [6] [7] . In addition, there has already been an article demonstrating that conventional contrast-enhanced CT might not be necessary when image fusion between PET and low-dose CT images is available using an inline PET/CT system [8] .
A CT device, as a part of a combined PET/CT scanner, is a multidetector-row CT, which can be used as a standalone CT scanner in clinical situations. To reduce radiation exposure and cost, low-dose CT is usually adopted without intravenous contrast in conventional PET/CT scanning, which may cause limitations in image interpretation [9] .
If full-dose CT scanning is performed with intravenous (IV) contrast, fused images between CT and PET may obtain more diagnostically valuable information to provide higher diagnostic accuracy. However, in monitoring or restaging after treatment in patients with lymphoma, systemic chemotherapy is under consideration for further therapeutic management. Therefore, unlike post-operative evaluation of colorectal cancer, it is not always necessary to detect each and every involved lesion, and patient-based evaluation is sufficient. However, whether low-dose unenhanced CT is sufficient after treatment or full-dose enhanced CT would be helpful to make 6 therapeutic decisions is still debatable.
The purpose of the current study was to compare the diagnostic performance between conventional PET/CT with low dose CT without contrast material (PET/ldCT) and PET/CT with full-dose CT and contrast enhancement (PET/ceCT). showed mild to moderate uptake with corresponding morphological abnormalities on CT, we also considered it positive; and when PET showed equivocal uptake without morphological abnormality or PET showed no uptake with or without morphological abnormality on CT, we regarded it as negative. Quantitative analysis was not conducted in this investigation.
Patients and methods

Patients
For monitoring after therapy, abnormal uptake indicating residual viable lesions was evaluated on patient-basis, and the difference of results was also assessed on region-basis. For restaging or follow-up, the sensitivity, specificity, and diagnostic accuracy were investigated on a patient-basis, based on clinical follow-up for at least 6 months, excluding three patients who died of lymphoma within 100 days after scanning, and the difference of diagnostic accuracy was evaluated. In addition, the difference of results between the two methods was also assessed on a region-basis.
All the patients were analyzed and there were no patients who were excluded from the analysis. For 13 patients who had repeated scans for restaging or follow-up purpose, only the initial results were used for calculating diagnostic performance.
Statistical analysis
McNemar test was used for evaluating difference of diagnostic performance, and Table 3 . Patient-based sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of PET+ldCT were 70%, 91%, 76%, 87%, and 84%, respectively, and those of PET+ceCT were 74%, 92%, 81%, 89%, and 87%, respectively. No statistically significant difference was found between the two scanning techniques, although discrepant results between the two methods occurred in 2 of 89 cases (2%). A recurrent tumor in the pons was accurately diagnosed only by PET/ceCT in one case (Fig. 1) , and intravenous thrombus was accurately diagnosed as negative involvement only by PET/ceCT in the other case (Fig. 2) . In both interpretation methods, positive findings in four patients turned out to be false. Focal uptake in the left palatine tonsil, bilateral submandibular glands, mediastinal, and supraclavicular nodes were interpreted as positive for relapse, but they were unchanged or disappeared without any treatment on follow-up PET/CT. In addition, extranodal focal uptake in the right thigh was regarded as relapse in one patient, but decreased in size one month later due to antibiotic treatment, indicating inflammatory change.
Discussion
In PET/CT examinations, our data shows that full-dose enhanced CT could be useful for accurate diagnosis in a small number of specific cases, while low-dose unenhanced CT may be enough in most cases after treatment of malignant lymphoma.
As a combined PET/CT scanner has been installed in many institutes, an increasing and concluded that PET/ceCT may be considered as the first-line diagnostic tool for restaging in patients with colorectal cancer [10] . For patients who were suspected of having recurrent ovarian cancer or uterine cervical cancer, PET/CT with contrast material yielded the most accurate diagnostic performance [11, 12] .
As for malignant lymphoma, it is still debatable whether or not IV contrast should be used in evaluating disease status. In initial staging, Rodriguez-Vigil et al. compared the diagnostic performance of PET/ldCT and PET/ceCT, and found one case in which a splenic hilar lesion was correctly diagnosed only via PET/ceCT, resulting in more accurate staging. However, there was no statistically significant difference between the two methods [13] . In contrast, Morimoto et al. demonstrated that more diagnoses that are accurate were acquired by PET/ceCT for evaluating pelvic lesions in initial staging of lymphoma [14] . In addition, Vera et al. proposed that contrast enhanced PET/CT 13 without low-dose CT is recommended as a one-stop imaging test for monitoring or restaging. CT with contrast material can be applicable for attenuation correction with minimal influence for quantitative values of lesions, and excess radiation exposure can be avoided by omitting low-dose CT [15] . In our series, two cases were accurately diagnosed only by PET/ceCT, but both PET/ldCT and PET/ceCT brought consistent results in the majority of cases. These findings were similar to our previous investigation [16] . When information obtained via PET is available, there are no significant differences in diagnostic performance, whether fused images between PET and CT are read, PET and CT are interpreted side-by-side, or only PET images are read.
In short, PET/ceCT is useful and yields the highest diagnostic accuracy, but PET/ldCT may be sufficient in most cases. Therefore, the use of intravenous contrast should be carefully considered for certain inconclusive cases to reduce medical cost. This strategy might also be useful to reduce adverse effects caused by iodine-based contrast material and to save medical cost without degrading diagnostic perfromance.
In this population, there was one false negative case using PET/ldCT interpretation in patients who had a PET/CT scan for restaging. In the false negative case, positive involvement of the central nervous system (CNS) could only be diagnosed by PET/ceCT as one FDG-avid lesion was enhanced in the pons, which was confirmed by MRI. It is well known that FDG accumulates in the brain, making it difficult to evaluate intracranial lesions. Therefore, if patients are suspected of having CNS involvement, the use of contrast material should be considered even in PET/CT studies.
One false positive case occurred due to intravenous thrombus. It is known that FDG also accumulates in thrombus probably due to the infiltration of inflammatory cells, which can cause a false positive result in FDG-PET imaging [17, 18] . This is a rarity, and accurate diagnosis was not obtained due to limited morphological information. In such a case, contrast material is helpful, but prior anticipation of accumulation in the thrombus may prove difficult, therefore the use of IV contrast should be considered when the possibility of uptake in the thrombus is suspected.
There are certain limitations in this study. Strictly speaking, we did not compare the It is reported that PET/ceCT was more accurate and helpful for evaluating hepatic lesions, compared to PET/ldCT, although it was a study for liever metastasis from colorectal cancer [19] . According to our previous data, even extra-nodal lesions were accurately diagnosed by PET, not by CT with contrast [16] , but further investigations with more cases of extra-nodal lesions is required to conclude that PET/ld CT would be sufficient for cases with extra-nodal lesions. The number in parentheses demonstrates the number of false positive results Intravenous thrombus was demonstrated corresponding to the uptake by ceCT (A:
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